Figure 2 from Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate–Resistant Prostate Cancer

Peripheral antibody and IFNγ ELISpot immune responses in AA men (n = 29) and non-AA men (n = 28). A, Significantly higher serum IgM antibody levels against PA2024 (P < 0.0001) and PAP (PAP; P < 0.0001) were noted at 10 weeks post-treatment above the baseline in each group. No significant differences were observed in either group for anti-PSMA antibody levels at 10 weeks post-treatment vs. baseline. There were significantly higher anti-PSA antibody levels in non-AA group (P = 0.0018) at 10 weeks post-treatment above the baseline. B, IFNγ ELISpot responses to PA2024 increased significantly (P = 0.0008) in non-AA men at 10 weeks post-treatment vs. baseline. In AA men, IFNγ ELISpot responses to PA2024 also increased (P = 0.04) at 10 weeks post-treatment. No significant differences in IFNγ ELISpot responses were seen at 10 weeks against PAP, PSMA, or PSA in either group. For (A and B), there were no significant racial differences in either antibody or IFNγ ELISpot responses against PA2024, PAP, PSMA, or PSA at baseline or at 10 weeks post-treatment. All responses and racial differences were analyzed by the Mann–Whitney test and P values < 0.0032 were considered as significant in the multiple comparisons sense. The horizontal line in each dot plot marks the median value. Base, baseline; wks, weeks.